Jay R. Luly

CIK: 0001571211

Transaction Breakdown

Open Market Buys (P)1 (8.3%)

High conviction signal

Open Market Sales (S)2 (16.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (41.7%)

Compensation grants

Other (G, F, J, C, D, …)4 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ENTA

ENANTA PHARMACEUTICALS INC

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2026
Award(A)
Direct
15.2K shares-
ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2026
Tax Payment(F)
Direct
6.2K shares at avg. $14.25$88K
ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2026
Award(A)
Direct
4.8K shares-
ENTA
ENANTA PHARMACEUTICALS INC
Dec 5, 2025
Sale(S)
Direct
4.7K shares at avg. $14.23$67K
ENTA
ENANTA PHARMACEUTICALS INC
Dec 1, 2025
Tax Payment(F)
Direct
1.9K shares at avg. $14.12$27K
ENTA
ENANTA PHARMACEUTICALS INC
Nov 25, 2025
Award(A)
Stock Option (right to buy)
Direct
310K shares-
ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2025
Award(A)
Direct
25.5K shares-
ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2025
Tax Payment(F)
Direct
7.5K shares at avg. $5.59$42K
ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2025
Purchase(P)
Direct
45K shares at avg. $5.69$256K
ENTA
ENANTA PHARMACEUTICALS INC
Dec 6, 2024
Sale(S)
Direct
5.1K shares at avg. $8.06$41K
ENTA
ENANTA PHARMACEUTICALS INC
Dec 1, 2024
Tax Payment(F)
Direct
3.8K shares at avg. $8.60$33K
ENTA
ENANTA PHARMACEUTICALS INC
Nov 27, 2024
Award(A)
Stock Option (right to buy)
Direct
250K shares-

		Type	Shares	Price		Ownership
Feb 12, 2026	ENTA ENANTA PHARMACEUTICALS INC	Award(A)	15,200	-	$0	Direct
Feb 12, 2026	ENTA ENANTA PHARMACEUTICALS INC	Tax Payment(F)	6,155	$14.25	$87,709	Direct
Feb 12, 2026	ENTA ENANTA PHARMACEUTICALS INC	Award(A)	4,800	-	$0	Direct
Dec 5, 2025	ENTA ENANTA PHARMACEUTICALS INC	Sale(S)	4,743	$14.23	$67,493	Direct
Dec 1, 2025	ENTA ENANTA PHARMACEUTICALS INC	Tax Payment(F)	1,885	$14.12	$26,616	Direct
Nov 25, 2025	ENTA ENANTA PHARMACEUTICALS INC	Award(A) Stock Option (right to buy)	310,000	-	-	Direct
Feb 12, 2025	ENTA ENANTA PHARMACEUTICALS INC	Award(A)	25,500	-	-	Direct
Feb 12, 2025	ENTA ENANTA PHARMACEUTICALS INC	Tax Payment(F)	7,484	$5.59	$41,836	Direct
Feb 12, 2025	ENTA ENANTA PHARMACEUTICALS INC	Purchase(P)	45,000	$5.69	$256,050	Direct
Dec 6, 2024	ENTA ENANTA PHARMACEUTICALS INC	Sale(S)	5,142	$8.06	$41,445	Direct
Dec 1, 2024	ENTA ENANTA PHARMACEUTICALS INC	Tax Payment(F)	3,829	$8.60	$32,929	Direct
Nov 27, 2024	ENTA ENANTA PHARMACEUTICALS INC	Award(A) Stock Option (right to buy)	250,000	-	-	Direct

1-12 of 12 transactions

About Luly Jay R.

Luly Jay R. (SEC CIK 0001571211) files insider reports with the SEC as President and CEO of ENANTA PHARMACEUTICALS INC (ENTA).

Signal8 holds 9 ownership filings by Luly Jay R., all Form 4s, filed between Nov 27, 2024 and Feb 13, 2026. Those filings report 12 transactions, from Nov 27, 2024 to Feb 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Luly Jay R.'s filings is in WATERTOWN, MA.

Recent filings by Luly Jay R.

Feb 12, 2026: Grant or award of ENTA shares (Form 4, code A).
Feb 12, 2026: Tax withholding of ENTA shares (Form 4, code F).
Feb 12, 2026: Grant or award of ENTA shares (Form 4, code A).
Dec 5, 2025: Open-market sale of ENTA shares (Form 4, code S).
Dec 1, 2025: Tax withholding of ENTA shares (Form 4, code F).

Other insiders filing for ENANTA PHARMACEUTICALS INC (ENTA)

Rottinghaus Scott T., Chief Medical Officer
Vance Terry, Director
Russell Lesley, Director
Peterson Kristine, Director
Hata Yujiro S, Director
FOLETTA MARK G, Director

How to read Form 4 transaction codes